TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Front Immunol
; 12: 637146, 2021.
Article
in En
| MEDLINE
| ID: mdl-34025646
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Receptors, Immunologic
/
Glioblastoma
/
Programmed Cell Death 1 Receptor
/
Immune Checkpoint Inhibitors
Type of study:
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Front Immunol
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
Switzerland